Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 1.9% – Time to Buy?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) shares shot up 1.9% on Thursday . The company traded as high as $3.27 and last traded at $3.24. 15,739 shares changed hands during mid-day trading, an increase of 86% from the average session volume of 8,450 shares. The stock had previously closed at $3.18.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on EPRX. RODMAN&RENSHAW upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price on the stock.

Eupraxia Pharmaceuticals Trading Up 1.2 %

The stock’s fifty day moving average is $3.12 and its two-hundred day moving average is $2.88. The firm has a market cap of $116.83 million and a P/E ratio of -4.56.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. Raymond James Financial Inc. acquired a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 11,613 shares of the company’s stock, valued at approximately $37,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.